Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01794741
Recruitment Status : Completed
First Posted : February 20, 2013
Results First Posted : March 31, 2015
Last Update Posted : March 31, 2015
Sponsor:
Information provided by (Responsible Party):
Meda Pharmaceuticals

Brief Summary:
This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: Dymista Nasal Spray Drug: Fluticasone propionate nasal spray Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 405 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis
Study Start Date : February 2013
Actual Primary Completion Date : November 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Dymista nasal spray
azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
Drug: Dymista Nasal Spray
Active Comparator: fluticasone propionate nasal spray
fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
Drug: Fluticasone propionate nasal spray



Primary Outcome Measures :
  1. Adverse Events Report [ Time Frame: 3 months of treatment ]
    reports of treatment emergent adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male and female subjects ≥ 4 years to <12 years, inclusive at the screening visit
  • A history of allergic rhinitis (AR)
  • The parent/caregiver must provide written informed consent and the child must provide assent
  • Willing and able to comply with the study requirements
  • Require treatment with Dymista Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subjects' clinical condition, at both the Screening and Randomization Visits
  • General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
  • Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)

Exclusion Criteria:

  • On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation
  • Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, clinically significant polyposis or clinically significant nasal structural abnormalities
  • Nasal surgery or sinus surgery within the previous year
  • The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
  • Presence of any hypersensitivity to azelastine hydrochloride and/or fluticasone propionate or drugs similar to azelastine hydrochloride and/or fluticasone propionate
  • Respiratory tract infections within two weeks prior to Visit 1.
  • Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
  • Chronic obstructive sleep apnea syndrome (clinical diagnosis)
  • Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
  • Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
  • Family members of research center or private practice personnel who are directly involved in this study are excluded
  • Members of the same family cannot enroll in the study at the same time.
  • Subjects who have used medications or therapies that could interfere with safety evaluations (see Sections 4.0 and 5.0) and have not had the proper washouts from these medications or therapies
  • Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
  • Positive pregnancy test in female subjects ≥ 9 years of age
  • Females who are pregnant or nursing practicing a medically acceptable method of contraception
  • Subjects who fail to complete the symptom diary during the lead-in period, defined as missing data for >50% of entries

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01794741


Locations
Show Show 41 study locations
Sponsors and Collaborators
Meda Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Nancy Ruiz, M.D. Sponsor GmbH
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Meda Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01794741    
Other Study ID Numbers: MP 4007
First Posted: February 20, 2013    Key Record Dates
Results First Posted: March 31, 2015
Last Update Posted: March 31, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents